INTERNATIONAL JOURNAL OF BIOPHARMACEUTICAL SCIENCES (ISSN:2517-7338)

Biography:

Nicola Micale, received the Ph.D. in Pharmaceutical Sciences at the University of Messina in 2000 From 2002 to 2006, he got a research contract within the project: "New Agents for the Treatment of Pathologies Neurodegenerative". In 2003-2004, he joined Prof. A. P. Kozikowski, first at the Department of Neurology, Georgetown University Medical Center, Washington DC, then at the Department of Medicinal Chemistry & Pharmacognosy, Illinois University, Chicago, where within the "Drug Discovery Program" he undertook a study on peptidomimetic cysteine protease inhibitors. In 2006 he received the “Farmindustria Prize” for the quality of his researches in the Medicinal Chemistry field. In 2006-2007 he was “Guest Professor” at the Department of Pharmaceutical Sciences, University of Copenhagen. From 2008 to 2017 he worked periodically and constantly as “Visiting Scientist” at the Institute of Pharmacy and Food Chemistry, Bavarian Julius-Maximilians-University of Wurzburg and at the Institute of Pharmacy and Biochemistry, Johannes Gutenberg University of Mainz within a steady research collaboration with Prof. Tanja Schirmeister. In 2013-2014 he worked for six months at the National Physical Laboratory of London within the “Biotechnology Group” of Dr. Max Ryadnov. He worked also as “Visiting Scientist” (2017) at the KU Leuven (BE), Department of Pharmaceutical and Pharmacological Sciences, Division of “Molecular Virology and Gene Therapy”. From 2008 he is Assistant Professor at the University of Messina and on January 29th, 2014 he was appointed as Associate Professor. His current research is mainly focused on biopolymers for the development of drug delivery systems for active and/or passive targeting of bioactive molecules and on design and synthesis of heterocyclic compounds targeting human and parasitic proteases.

Research Interests:

• “Synthesis and characterization of biopolymers for the development of drug delivery systems for active and/or passive targeting of bioactive molecules”.
• “Design and synthesis of conformationally constrained peptidomimetics as inhibitors of parasitic cysteine proteases”.
• Identifications, design and synthesis of new anti-cancer agents. Selected targets: i) human 20S proteasome; ii) HDACs; iii) Hsp90.